| SC 13G/A | 2022-02-09 | FMR LLC | Nabriva Therapeutics plc | 2,215,958 | 3.8% | EDGAR |
| SC 13G | 2021-11-19 | Lincoln Park Capital Fund, LLC | Nabriva Therapeutics plc | 4,512,589 | 8.0% | EDGAR |
| SC 13G/A | 2021-02-08 | FMR LLC | Nabriva Therapeutics plc | 1,429,259 | 6.8% | EDGAR |
| SC 13G/A | 2020-02-12 | Longitude Capital Partners II, LLC | Nabriva Therapeutics plc | 4,256,527 | 4.5% | EDGAR |
| SC 13G | 2020-02-07 | FMR LLC | Nabriva Therapeutics plc | 6,131,900 | 6.5% | EDGAR |
| SC 13D/A | 2019-12-26 | ORBIMED ADVISORS LLC | Nabriva Therapeutics plc | 4,644,600 | 4.9% | EDGAR |
| SC 13D/A | 2019-12-06 | ORBIMED ADVISORS LLC | Nabriva Therapeutics plc | 4,644,600 | 5.9% | EDGAR |
| SC 13G/A | 2019-08-14 | Vivo Capital VIII, LLC | Nabriva Therapeutics plc | 3,528,566 | 4.8% | EDGAR |
| SC 13G/A | 2019-07-01 | Novo Holdings A/S | Nabriva Therapeutics plc | 3,446,564 | 4.7% | EDGAR |
| SC 13G/A | 2019-02-14 | venBio Global Strategic Fund II L.P. | Nabriva Therapeutics plc | 0 | 0.0% | EDGAR |
| SC 13G/A | 2019-02-14 | HBM Healthcare Investments (Cayman) Ltd. | Nabriva Therapeutics plc | 1,834,007 | 2.7% | EDGAR |
| SC 13G/A | 2019-02-14 | Frazier Healthcare VII, L.P. | Nabriva Therapeutics plc | 3,312,546 | 4.9% | EDGAR |
| SC 13G/A | 2019-02-14 | Vivo Capital VIII, LLC | Nabriva Therapeutics plc | 4,801,333 | 7.2% | EDGAR |
| SC 13G/A | 2019-02-11 | WELLINGTON MANAGEMENT GROUP LLP | Nabriva Therapeutics plc | 0 | 0.0% | EDGAR |
| SC 13G/A | 2019-02-08 | WELLINGTON MANAGEMENT GROUP LLP | Nabriva Therapeutics plc | 3,594,568 | 5.4% | EDGAR |
| SC 13G/A | 2019-02-01 | Novo Holdings A/S | Nabriva Therapeutics plc | 4,703,720 | 7.0% | EDGAR |
| SC 13G/A | 2018-08-10 | WELLINGTON MANAGEMENT GROUP LLP | Nabriva Therapeutics plc | 5,031,676 | 7.6% | EDGAR |
| SC 13G | 2018-08-07 | Longitude Capital Partners II, LLC | Nabriva Therapeutics plc | 4,012,375 | 6.0% | EDGAR |
| SC 13G/A | 2018-08-06 | Vivo Capital VIII, LLC | Nabriva Therapeutics plc | 4,801,333 | 7.2% | EDGAR |
| SC 13G | 2018-08-03 | Frazier Healthcare VII, L.P. | Nabriva Therapeutics plc | 3,122,540 | 4.7% | EDGAR |